GRO Biosciences Inc. closes $60.3M Series B financing co-led by Atlas Venture and Access Biotechnology
Amount Raised
$60.3 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
GRO Biosciences Inc. has closed an oversubscribed $60.3 million Series B financing. The funds will be used to advance the company’s lead program into the clinic for the treatment of refractory gout, to broaden the GRObio pipeline, and to expand its genomically recoded organism (GRO) platform for scalable production of therapeutics incorporating multiple non-standard amino acids (NSAAs).
Quick answer
GRO Biosciences raised $60.3 Million in a Series B round, dated July 19, 2024. Investors: Innovation Endeavors, Digitalis Ventures, Redmile Group, Leaps By Bayer, Access Biotechnology and Atlas Venture. GRO Biosciences is based in Cambridge, Massachusetts, United States.
- How much did GRO Biosciences raise?
- GRO Biosciences raised $60.3 Million in a Series B round on July 19, 2024.
- Who invested in GRO Biosciences?
- Innovation Endeavors, Digitalis Ventures, Redmile Group, Leaps By Bayer, Access Biotechnology and Atlas Venture are named as investors in this round.
- What does GRO Biosciences do?
- GRO Biosciences is an emerging biotechnology company leveraging synthetic biology to expand the amino acid alphabet and deliver on the promise of protein therapeutics.
- Where is GRO Biosciences based and how big is it?
- GRO Biosciences is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at GRO Biosciences?
- Fundz holds 1 contact at GRO Biosciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as GRO Biosciences that raised within 45 days of this round, from Fundz verified event records.
- Radiant raised $34M on August 27, 2024.
- Navigator Medicines raised $100M (Series A) on August 27, 2024.
- Diakonos Oncology raised $11M (Seed) on August 26, 2024.
- Navigator Medicines raised $50M on August 23, 2024.
- Borealis Biosciences raised $150M (Series A) on August 22, 2024.
- Retension Pharmaceuticals raised $10M (Series A) on August 21, 2024.
Who to call at GRO Biosciences, and when
A new round usually means GRO Biosciences is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GRO Biosciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GRO Biosciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GRO Biosciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GRO Biosciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansGRO Biosciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.